Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

07:45
10/17/16
10/17
07:45
10/17/16
07:45

Celgene data better than expected, says Wells Fargo

After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.

TODAY'S FREE FLY STORIES

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Earnings
Teleflex reports Q4 adjusted EPS $2.13, consensus $2.09 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

DORM

Dorman Products

$77.94

5.68 (7.86%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Downgrade
Dorman Products rating change  »

Dorman Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$85.73

-0.95 (-1.10%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Earnings
Zebra Technologies reports Q4 EPS $1.93, consensus $1.73 »

Reports Q4 revenue $942M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

WAAS

AquaVenture

$18.01

0.69 (3.98%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Upgrade
AquaVenture rating change  »

AquaVenture upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:32
02/23/17
02/23
06:32
02/23/17
06:32
Hot Stocks
Breaking Hot Stocks news story on SAGE Therapeutics »

SAGE Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Earnings
Breaking Earnings news story on SAGE Therapeutics »

SAGE Therapeutics reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Recommendations
Labarge analyst commentary  »

L Brands selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$30.09

-0.19 (-0.63%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Periodicals
Suez in the running for General Electric's water unit, Reuters reports »

France's Suez is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

DLHC

DLH Holdings Corp.

$5.27

-0.08 (-1.50%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Initiation
DLH Holdings Corp. initiated  »

DLH Holdings Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$89.90

0.44 (0.49%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Earnings
CIBC reports Q1 adjusted EPS C$2.89, consensus C$1.96 »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMRE

Global Medical REIT

$8.48

0.06 (0.71%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Initiation
Global Medical REIT initiated  »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:25
02/23/17
02/23
06:25
02/23/17
06:25
Hot Stocks
Teleflex CEO Benson Smith retiring at end of 2017, succeeded by COO Liam Kelly »

Teleflex CEO Benson Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MBLY

Mobileye

$47.42

1.3 (2.82%)

06:22
02/23/17
02/23
06:22
02/23/17
06:22
Recommendations
Mobileye analyst commentary  »

Mobileye price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:20
02/23/17
02/23
06:20
02/23/17
06:20
Hot Stocks
Carter's raises quarterly dividend 12% to 37c per share »

For payment on March 24…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:19
02/23/17
02/23
06:19
02/23/17
06:19
Earnings
Carter's sees FY17 adjusted EPS growth 8%-10%, consensus $5.52 »

For fiscal 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:18
02/23/17
02/23
06:18
02/23/17
06:18
Earnings
Carter's sees Q1 adjusted EPS 80c-85c, consensus $1.14 »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NVCR

Novocure

$7.15

-0.15 (-2.05%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Hot Stocks
Novocure Chief Commercial Officer Peter Melnyk departing »

Novocure's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Periodicals
Credit Suisse allocates $600M to expand Saudi Arabia business, Bloomberg says »

Credit Suisse is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OUT

OUTFRONT Media

$26.89

-0.44 (-1.61%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Downgrade
OUTFRONT Media rating change  »

OUTFRONT Media downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Breaking Hot Stocks news story on Carter's »

Carter's raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Energy Focus sees Q1 restructuring charges of $1.1M »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Earnings
Carter's reports Q4 adjusted EPS $1.79, consensus $1.67 »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CMVT

Comverse

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Periodicals
Former Comverse CEO faces sentencing in fraud case, Reuters reports »

Jacob "Kobi"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Recommendations
Energy Focus analyst commentary  »

Energy Focus reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

, MON

Monsanto

$111.38

0.81 (0.73%)

06:13
02/23/17
02/23
06:13
02/23/17
06:13
Periodicals
Bayer looks to raise $19B in equity to fund proposed Monsanto deal, WSJ reports »

Bayer (BAYRY) is looking…

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

MON

Monsanto

$111.38

0.81 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

  • 01

    Apr

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.